THE FIRST NEW MONOTHERAPY THERAPEUTIC PBC STUDY IN A DECADE? AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID IN PBC

被引：7
|
作者：
Jones, D. [1 ]
Kowdley, K. [2 ]
Chapman, R. [3 ]
Burroughs, A. [4 ]
Hirschfield, G. [5 ]
Schramm, C. [6 ]
Poupon, R. [7 ]
ParEs, A. [8 ]
Shapiro, D. [9 ]
Pruzanski, M. [9 ]
机构：
[1] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] Virginia Mason Med Ctr Seattle, Seattle, WA USA
[3] Univ Oxford, Oxford OX1 2JD, England
[4] Royal Free Hosp, London NW3 2QG, England
[5] Univ Toronto, Toronto, ON M5S 1A1, Canada
[6] Univ Hamburg, Hamburg, Germany
[7] Hosp St Antoine, Paris, France
[8] Barcelona Clin, Barcelona, Spain
[9] Intercept Pharmaceut, New York, NY USA
来源：
GUT | 2011年 / 60卷
关键词：
D O I：
10.1136/gutjnl-2011-300857b.2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP02
引用
收藏
页码：A50 / A50
页数：1
相关论文
共 50 条
  • [1] THE FIRST NEW MONOTHERAPY THERAPEUTIC PBC STUDY IN A DECADE? AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID IN PBC
    Kowdley, Kris V.
    Luketic, Velimir A.
    Jones, David E.
    Chapman, Roger W.
    Burroughs, Andrew K.
    Hirschfield, Gideon M.
    Poupon, Raoul
    Schramm, Christoph
    Vincent, Catherine
    Rust, Christian
    Pares, Albert
    Mason, Andrew L.
    Castelloe, Erin N.
    Sciacca, Cathi I.
    Boehm, Olaf
    Pruzanski, Mark
    Shapiro, David A.
    HEPATOLOGY, 2011, 54 : 416A - 417A
  • [2] AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC
    Kowdley, K. V.
    Jones, D.
    Luketic, V.
    Chapman, R.
    Burroughs, A.
    Hirschfield, G.
    Poupon, R.
    Schramm, C.
    Vincent, C.
    Rust, C.
    Pares, A.
    Mason, A.
    Sciacca, C.
    Beecher-Jones, T.
    Bohm, O.
    Castelloe, E.
    Pruzanski, M.
    Shapiro, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S13 - S13
  • [3] The First New Trials for Primary Biliary Cirrhosis in a Decade: An International Program Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid
    Kowdley, Kris y
    Nevens, Frederik
    Andreone, Pietro
    Luketic, Velimir A.
    Shah, Hemant
    Pencek, Richard
    Marmon, Tonya K.
    Shapiro, David
    GASTROENTEROLOGY, 2015, 148 (04) : S991 - S992
  • [4] FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF DRUGS FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF OBETICHOLIC ACID (INT-747) TO URSODEOXYCHOLIC ACID
    Mason, Andrew L.
    Luketic, Velimir A.
    Lindor, Keith D.
    Hirschfield, Gideon M.
    Gordon, Stuart C.
    Mayo, Marlyn J.
    Kowdley, Kris V.
    Pares, Albert
    Trauner, Michael
    Sciacca, Cathi I.
    Jones, Tessa Beecher
    Pruzanski, Mark
    Shapiro, David A.
    HEPATOLOGY, 2010, 52 (04) : 357A - 357A
  • [5] THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES - AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS
    Nevens, F.
    Andreone, P.
    Mazzella, G.
    Strasser, S.
    Bowlus, C.
    Invernizzi, P.
    Drenth, J.
    Pockros, P.
    Regula, J.
    Hansen, B.
    Hooshmand-Rad, R.
    Sheeron, S.
    Shapiro, D.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S525 - S526
  • [6] FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACID
    Mason, A.
    Luketic, V.
    Lindor, K.
    Hirschfield, G.
    Gordon, S.
    Mayo, M.
    Kowdley, K.
    Pares, A.
    Trauner, M.
    Castelloe, E.
    Sciacca, C.
    Jones, T. B.
    Boehm, O.
    Shapiro, D.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S1 - S2
  • [7] A LONG TERM SAFETY EXTENSION TRIAL OF THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) AND UDCA IN PRIMARY BILIARY CIRRHOSIS (PBC)
    Hirschfield, Gideon M.
    Mason, Andrew L.
    Gordon, Stuart C.
    Luketic, Velimir A.
    Mayo, Marlyn
    Vincent, Catherine
    Lindor, Keith D.
    Pares, Albert
    Kowdley, Kris V.
    Trauner, Michael
    Esguerra, Maria
    Boehm, Olaf
    Shapiro, David A.
    HEPATOLOGY, 2011, 54 : 429A - 429A
  • [8] Obeticholic Acid in primary biliary Cholangitis PBC OCA International Study of Ffficacy (POISE)
    Gerken, G.
    Nitschmann, S.
    INTERNIST, 2017, 58 (02): : 202 - 204
  • [9] LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC)
    Hirschfield, G.
    Kowdley, K.
    Mason, A.
    Luketic, V.
    Gordon, S.
    Vincent, C.
    Mayo, M.
    Pares, A.
    Chapman, R.
    Lindor, K.
    Esguerra, M.
    Eliot, L.
    Shapiro, D.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S372 - S372
  • [10] THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC)
    Marschall, H. -U.
    Luketic, V.
    Lovgren-Sandblom, A.
    Benthin, L.
    Kowdley, K.
    Hirschfield, G.
    Mason, A.
    Lindor, K.
    Gordon, S.
    Vincent, C.
    Chapman, R.
    Mayo, M.
    Burroughs, A.
    Pares, A.
    Jones, D.
    Schramm, C.
    Eliot, L.
    Hofmann, A. F.
    Shapiro, D.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S377 - S377
12345